Clemson University

TigerPrints
All Theses

8-2010

FOSINOPRIL, A POTENTIAL SUBSTRATE
FOR MRP2, COMPETES WITH SEVERAL
HIGH USE PHARMACEUTICALS FOR
ELIMINATION
Benjamin Green
Clemson University, funboygreen@yahoo.com

Follow this and additional works at: https://tigerprints.clemson.edu/all_theses
Part of the Molecular Biology Commons
Recommended Citation
Green, Benjamin, "FOSINOPRIL, A POTENTIAL SUBSTRATE FOR MRP2, COMPETES WITH SEVERAL HIGH USE
PHARMACEUTICALS FOR ELIMINATION" (2010). All Theses. 893.
https://tigerprints.clemson.edu/all_theses/893

This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized
administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

Theses

FOSINOPRIL, A POTENTIAL SUBSTRATE FOR MRP2, COMPETES WITH
SEVERAL HIGH USE PHARMACEUTICALS FOR ELIMINATION

A Thesis
Presented to
the Graduate School of
Clemson University

In Partial Fulfillment
of the Requirements for the Degree
Master of Science
Biological Sciences

by
Benjamin Robert Green
August 2010

Accepted by:
Dr. Lisa J. Bain Committee Chair
Dr. Peter van den Hurk
Dr. Tzuen-Rong J. Tzeng

Abstract
The multidrug-resistance associated protein 1 (MRP1) and multidrug-resistance
associated protein 2 (MRP2) are membrane transporters responsible for the efflux of
endogenous compounds, a variety of drugs, along with other xenobiotics. They are two
of the most highly expressed transporters, but are localized on opposite sides of polarized
membranes: MRP1 is on the basolateral side, while MRP2 is on the apical side. Since
MRP1 and MRP2 can eliminate such a wide variety of compounds from cells, thereby
reducing their half-life, assessing the transport of highly prescribed pharmaceuticals via
MRP transporters either alone or in mixtures is important to determine the potential for
drug-drug interactions. MDCK cells transfected with the MRP1 and MRP2 gene were
used to assess drugs as potential substrates by examining their differential toxicity,
accumulation, and efflux. Based upon initial screening assays, three high-use
pharmaceuticals, fosinopril, loratadine, and desloratadine were assessed, along with the
known substrates vincristine and methotrexate as positive controls. MRP1overexpressing cells were 1.4-fold less sensitive to the toxicity of loratadine and 2-fold
less sensitive to fosinopril. MRP2-overexpressing cells were 2.4-fold less sensitive to
fosinopril than controls, while cells showed no difference in sensitivity to desloratadine.
We then conducted accumulation/efflux assays to help substantiate that these compounds
were indeed substrates for the MRP1 and MRP2 transporters. The positive control,
vincristine, was transported out of the MRP1-overexpressing cells more rapidly, with
56% of the compound remaining compared to 85% of the vincristine remaining in the
MDCK cells. The other positive control, methotrexate, accumulated 1.5-fold less in
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MRP2 cells compared to controls. MRP1 and MRP2 only showed slight differences in
their ability to transport loratadine. MRP1 cells retained 52% of the loratadine and 53%
remained in MRP2 cells compared to 63% remaining in control cells. MRP2overexpressing cells effluxed desloratadine significantly more rapidly, as 56% of the
accumulated desloratadine remained in MRP2-overexpressing compared to 66% retention
in the MDCK cells. More impressively, fosinopril only retained 13% in MRP2 cells
while the MDCK cells retained 60%.

Since fosinopril appeared to be a good substrate for MRP2, we used it to perform
mixture assays to assess the possibility of drug-drug interactions. Cells were incubated
with fosinopril along with loratadine, desloratadine, or methotrexate to determine if the
second drug would increase the retention of fosinopril. When fosinopril was combined
with desloratadine, its retention was increased by 2-fold, with loratadine, its retention was
increased by 4.7-fold, and with methotrexate the retention was increased by 2-fold. The
increase in retention with multiple drugs likely indicates that a drug-drug interaction is
occurring. We then dosed wild-type and Mrp2 knockout mice with methotrexate, a
known Mrp2 substrate, and fosinopril. In mice lacking Mrp2, fosinopril and
methotrexate levels are increased in the serum and the kidneys, which suggest that Mrp2
is needed to eliminate fosinopril. This also suggests that with the absence of Mrp2 there
is a shift from the fecal to urinary elimination, which could potentially lead to toxic levels
if no compensatory mechanism takes over. The body’s ability to adapt to changes made
by drug-drug interactions is vital for survival. Assessing the transport of highly
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prescribed pharmaceuticals by MRP transporters is important to determine the potential
for drug-drug interactions, and will aid clinicians in minimizing drug toxicity.

Key words: Multidrug resistance-associated protein 2, fosinopril, methotrexate
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1. Introduction:
A large variety of the anionic substrates are transported across the cellular
membranes through the use of ABC transporters. ABC transporters are members of one
of the largest super families, containing more than 48 members, which all require ATP to
mediate transport (Dean, 2001). The MRP family (also known as ABCC), along with the
cystic fibrosis regulator (ABCC7) makes up this MRP subfamily that contains 12 full
transporters. Functioning in the elimination of many of the endogenous and xenobiotic
compounds, some of the compounds transported by these proteins are bile salts, lipids,
steroids, anticancer agents and drugs (Roger et al., 2006).

In order for many pharmaceuticals and physiological substrates to be excreted by
the body, they first have to go through several biotransformation steps. Many times this
multistep biotransformation process involves phase I and phase II enzymes. In the first
phase, substances are hydrolyzed, reduced, or oxidized to add a functional group to the
compound, which is oftentimes done by a family of enzymes called the cytochrome
P450s. Following this first phase, one transformation substance will go through a
conjugation reaction with a glucuronide, sulfate, or glutathione group added on by phase
II enzymes. Adding on one of these cofactors make the lipophilic compounds more
water-soluble and more likely to be excreted via the urine or the bile. This addition of a
bulky hydrophilic group may also flag the compound to be substrate for MRP
transporters.
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Every year there are over 2.2 million people injured by prescription drugs alone
(Watson et al., 2008). With the MRP’s having such a diverse substrate specificity and
ubiquitous location in the body, there are many situations in which potential drug-drug
interactions could result. The most studied examples of drug-drug interactions involve
situations where two drugs are metabolized by the same enzyme. P450s are one such
superfamily of enzymes that are extremely important in the phase I metabolism of many
drugs (reviewed in Omari et al, 2007). Certain drugs may increase the amount of P450s
present and speed up the oxidation and clearance of a second drug. A good example of
this type of drug-drug interaction is the induction of CYP2C9 by rifampin (Zakia, 2008).
Among the substrates of CYP2C9 is the anticoagulant warfarin. If someone was
depending on warfarin acting as a blood thinner, increasing its metabolism by the
addition of a second drug could potentially result in a blood clot, stroke, or heart attack
(Zakia, 2008). A search of the literature reveals that most published drug-drug
interactions are mediated via P450s, as they describe how inactivation of CYP’s could
result in clinically relevant drug interactions and adverse drug reactions. Drug-drug
interactions can result in a prolonged half-life of the compound or a higher concentration
in the organs, which, if not put in check, can lead to toxic effects (Leucuta et al., 2006;
Zhou et al., 2006). However, there are few studies investigating drug-drug interactions
via phase II enzymes.

For the past few decades there have been many advances in the characterization
and function of these transport proteins. Their role in the absorption, distribution,
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metabolism and excretion of drugs, and endogenous compounds and other xenobiotics
through the liver, kidneys and other tissues is very important (van de Water et al., 2005).
Two of the biggest players involved in therapeutic compounds and toxicologically
relevant drug resistance and in drug transport are the MRP1 and MRP2 proteins. They
pump in opposite directions (basolateral vs. apical) and have been shown to contribute to
drug elimination (Keppler et al., 1997; Kruh et al., 2001; Zhou et al., 2008).

MRP1 (ABCC1)
Multidrug resistance-associated protein 1 was first identified because of its ability
to eliminate cytotoxic drugs from lung tumor cells (Cole et al., 1992). These cells were
selected by being exposed to the anthracycline doxorubicin repeatedly (Cole et al., 1992).
Although discovered with the use of a single drug, MRP1 cells are also resistant to a
large variety of structurally unrelated anticancer compounds, such as vincristine,
daunorubicin, and methotrexate and can transport physiological products, such as
conjugated steroid hormones and bile salts. MRP1 can also transport drugs, such as
flutamide, (an antiandrogen), ritonavir, (an antiviral), or difloxacin and grepafloxacin,
(both antibiotics) (reviewed in Munoz et al., 2007; Sasabe et al., 2004; van de Water et
al., 2005; Zaman et al., 1994). MRP1 expression is restricted to the basolateral side of
certain tissues, including kidney, lung, intestine, brain, testis, macrophages, epithelial
cells, and hepatocytes, although the expression of MRP1 in the liver is somewhat low
(Flens et al., 1996; van de Water et al., 2005; Wijnholds et al., 1998). MRP1’s highest
expression can be found in the kidney, with expression in the distal tubule, collecting
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duct tubule, and loop of Henle (Rothnie et al., 2008). MRP1 overexpression has been
seen in a variety of solid tumors, such as in the lung, breast, and prostate, which shows to
be problematic when pharmaceutical therapy is administered. The overexpression of the
MRP1 increases the elimination of therapeutic compounds, thereby decreasing their
effectiveness (Munoz et al., 2007).

MRP1’s ability to transport a variety of conjugated substrates is confirmed by in
vitro and in vivo studies using models lacking Mrp1. For example, one study showed that
mouse cell lines lacking the Mrp1 gene were substantially more susceptible to drugs
compared to wild-type mice cells lines. Some of the drugs examined were
epipodophyllotoxins, whose toxicity increased 4 –7-fold in the knockout cell lines,
camptothecins (3-fold increase), arsenite (4-fold increase), anthracyclines (6 –7 fold
increase), and vincristine (28-fold increase in toxicity) (Allen et al., 2000). Another
study showed that there is elevated intracellular accumulation and a decreased excretion
of leukotriene C4 (an MRP1 substrate). As a result, the secretion of this product
decreased to about 1/4 of normal levels found in cultured bone marrow mast cells of Mrp
-/-

mice (Wijnholds et al., 1997). Mrp1-/- mice showed a decrease in body weight and

fatalities at etoposide concentrations that were not normally fatal to wild-type mice
(Wijnholds et al., 1997). In a study done on the drug grepafloxacin, an oral broadspectrum quinoline antibacterial, the ratio of the drug found in the tissue compared to the
drug found in the plasma was significantly higher in the heart, trachea, kidney, spleen,
and brown fat of Mrp1-/- mice than the drug found in wild-type mice (Sasabe et al., 2004).
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These findings demonstrate the importance of the MRP1 protein and its role in
eliminating certain compounds.

MRP2 (ABCC2)
Although the function of the second member of the ABCC family had been
known for years, the discovery of its gene did not occur until 4 years after the discovery
of MRP1 (Borst et al., 2000). The MRP2 transporter was originally known as the
canalicular multispecific organic anion transporter (cMOAT). TR-/GY rats were used for
many years to study defects in the excretion of many negatively charged, amphiphilic
organic anions, such as bilirubin-glucuronide (Borst et al., 2000), and are now known to
have defective mutations in their ABCC2/cMOAT/MRP2 gene (Paulusma et al., 1996).
The TR- rat’s phenotype is similar to that of patients with Dubin-Johnson syndrome,
which is characterized by jaundice, the result of chronic conjugated hyperbilirubinemia,
caused by impaired hepatobiliary elimination of many organic compounds (Paulusma et
al., 1996; Paulusma et al., 1997).

The Mrp2 protein product has been shown to be expressed on the apical
membrane (Keppler et al., 1997). MRP2 tends to be more restricted in its tissue
distribution than MRP1, being localized in the liver, gallbladder, kidney, small intestine,
colon, placenta, and lung (Bandler et al., 2008). The coordinate induction of MRP2 and
several phase II enzymes is, in part, regulated by a nuclear transcription factor termed the
constitutive androstane receptor (CAR) (Johnson et al., 2002; Kast et al., 2002). MRP2
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functions as a transporter of a variety of drugs and xenobiotics, such as bilirubin, sulfated
bile salts, non-conjugated compounds, and cytotoxic agents: etoposide, vinblastine,
cisplatin, methotrexate, doxorubicin, and epirubicin (Bandler et al., 2008; reviewed in
van de Water et al., 2005). MRP2, along with MRP1 and MRP3, shows considerable
overlap in the substrate specificity, which is supported by the fact that it has a high
amino-acid homology (Bakos et al., 2000). The MRP2 was found to eliminate
glutathione conjugates like leukotriene C4, S-(2, 4-dinitrophenyl)-glutathione, and Nethylmaleimide glutathione, along with glutathione (reviewed in van de Water et al.,
2005).

Like MRP1, MRP2 transports GSH and GSSH, and therefore is also thought to

help protect the cell from oxidative stress (Roger et al., 2006).

The MRP2 transporters have also shown to be expressed in various colorectal,
hepatic, mesothelial, lung, ovarian, and leukemic cancer cells (Hoffmann et al., 2004).
This leads to the assumption that MRP2 may be a potential obstacle in the use of certain
chemotherapeutic agents. A clinical study on breast cancer indicated that the use of
Ionafarnib, a MRP2 inhibitor, along with cisplatin and/or 5-fluorouracil, resulted in
reduction of the chemotherapy dosage and could become less toxic (Hoffmann et al.,
2004).

As stated previously, much of what we know about the MRP2 protein was
performed on TR- rats. The TR- rats are compromised in their ability to effectively
eliminative compounds via biliary secretion. In a study on TR- rats, it was found there
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was dramatic reduction in the rats’ ability to eliminate bromosulfophthalein by 15 %,
dibromosulfophthalein by 50 %, and indocyanine green by 75%, compared to that of
normal levels (Jansen et al., 1993). Although the original finding of the MRP2
transporter was done in rats, there have been many studies done with mice. For example,
after the food-derived, oral administration of carcinogens PhIP (2-amino-1-methyl 6phenylimidazo [4,5- b]pyridine) there was a 1.9-fold increase in the plasma levels in the
Mrp2-/- mice versus wild-type mice. In the same study there was a 1.7-fold increase in
plasma levels of oral-administered IQ (2-amino-3-methylimidazo[4,5-f]quinoline) in
Mrp2-/- mice versus wild-type mice, suggesting that Mrp2 may be reducing exposure to
these compounds (Vlaming et al., 2006). The Mrp2-deficient mice displayed decreased
total bilirubin and glutathione in bile and increased levels of bilirubin in urine, indicating
that urinary excretion may serve as an alternate excretion pathway for certain compounds
in these mice (Vlaming et al., 2006). In a study on spiramycin, which is used to treat
respiratory infections, it was found that there was a 10-fold decrease in the rate of biliary
excretion of spiramycin in Mrp2 knockout mice (Xianbin et al., 2007). It has been shown
that Mrp2 is one of the major regulators of biliary elimination of methotrexate (MTX)
and its toxic metabolite 7-hydroxymethotrexate (7OH-MTX) in mice. In this study it was
found the up-regulation of Mrp2, along with the absences of the breast cancer resistance
protein, another important anionic transporter, mice reduced biliary excretions of MTX
and/or 7OH-MTX, which resulted in increased plasma levels of 7OH-MTX. Levels of
MTX in the kidneys also increased by 7-fold and liver levels of 7OH-MTX increased 90fold (Vlaming et al., 2009).
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Assessing the transport of highly prescribed pharmaceuticals via MRP
transporters either alone or in mixtures is important to determine the potential for drugdrug interactions. In the present study, we examined fosinopril, an angiotensin
converting enzyme (ACE) inhibitor, loratadine and desloratadine, both antihistamines, to
determine if they were substrates for the MRP transporters, and if so, whether they could
alter the transport and toxicity of one another. The pharmaceuticals of interest all have a
high molecular weight, multiple rings, and are excreted from the body predominantly as
conjugates. The aim of this study was to examine whether these drugs interact by
inhibiting one another’s excretion from cells via the multidrug resistance-associated
proteins 1 and 2.
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Abstract
The multidrug-resistance associated protein 2 (MRP2) is a membrane-bound
transporter responsible for the efflux of a variety of drugs and endogenous compounds.
MDCK cells transfected with the human MRP2 gene were used to assess whether several
highly used pharmaceuticals were potential substrates by examining their differential
toxicity, accumulation, and efflux. Fosinopril, an ACE inhibitor, was 2.4-fold less toxic
to the MRP2 transfected cells compared to mock transfected cells, suggesting that
fosinopril is a potential MRP2 substrate. In addition, fosinopril was effluxed more
rapidly, as the MRP2 cells only retained 13% of the dosed fosinopril after 20 minutes
compared with 60% retained in the control cells. To determine whether fosinopril might
contribute to a drug-drug interaction, fosinopril efflux was examined in combination with
several other known or suspected MRP2 substrates. When fosinopril was coincubated
with desloratadine, its retention was increased by 2-fold; with loratadine, its retention was
increased by 4.7-fold, and with methotrexate, its retention was increased by 2-fold. The
increases in retention with multiple drugs likely indicate that a drug-drug interaction is
occurring. To further clarify whether fosinopril was a substrate for Mrp2, we dosed wildtype and Mrp2 knockout mice with the known Mrp2 substrate methotrexate and
fosinopril. In mice lacking Mrp2, fosinopril and methotrexate levels were increased in
the serum and the kidneys, which suggest that the lack of Mrp2 favors fosinopril
excretion through the urine rather than the feces. Assessing the transport of highly
prescribed pharmaceuticals by MRP transporters is important to determine the potential
for drug-drug interactions, and will aid clinicians in minimizing drug toxicity.
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1. Introduction:
Multidrug resistance-associated protein 1 and 2 (MRPs) are membrane-bound
transporters that efflux a variety of drugs, other xenobiotics, as well as endogenous
compounds (Homolya et al., 2003; Kruh et al., 2007; van de Water et al., 2005).
Substrates for MRP1 include a large variety of structurally unrelated anticancer
compounds such as doxorubicin, vincristine, daunorubicin, colchicines, and etoposide,
physiological products, such as conjugated steroid hormones, leukotriene C4, and bile
salts, and drugs such as grepafloxacin, (Allen et al., 2000; Bakos et al., 2000; Cole et al.,
1994; Jedlitschky et al,. 1997; Sasabe et al., 2004; Zaman et al., 1994) saquinavir
(Williams et al., 2002), chloroquine (Vezmar et al., 1998), and ethacrynic acid (Zaman et
al., 1996). In vivo studies with mice lacking Mrp1 have confirmed some of these
substrates. For example, Mrp1-/- mice have significant increases in the levels of the
antibiotic grepafloxacin in the heart, trachea, kidney, spleen, and brown fat compared to
wild-type mice (Sasabe et al., 2004). The secretion of leukotreine C4 is diminished in
cultured bone marrow mast cells of Mrp1 -/- mice and these mice are hypersensitive to the
toxicity of etoposide, which damages the mucosal layer of the tongue and cheek, and
inhibits spermatogenesis (Wijnholds et al., 1997; Wijnholds et al., 1998).

MRP2 and MRP1 show considerable overlap in the substrate specificity, since
they have a high amino acid homology (Bakos et al., 2000). MRP1 is expressed in most
tissues, including the kidney, lung, intestine, brain, testis, macrophages, and hepatocytes,
and it is localized to the basolateral side of polarized epithelial cells (Flens et al., 1996;
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van de Water et al., 2005; Wijnholds et al., 1998). The MRP2 protein product is
expressed on the apical membrane (Keppler et al., 1997), and tends to be a more
restricted in its tissue distribution than MRP1, being localized in the liver, gallbladder,
kidney, small intestine, colon, placenta, and lung (Bandler et al., 2008). Like MRP1,
MRP2 also transports a variety of physiological substrates and drugs, such as bilirubin,
sulfated bile salts, etoposide, methotrexate, adefovir, chloroquine, loperamide,
naringenin, sulfusalazine, and tamoxifen (Bakos et al., 2000; Jedlitschky et al,. 1997;
Pedersen et al., 2008). Other pharamaceuticals, such as saquinavir (Williams et al.,
2002), docetaxel (Zimmermann et al., 2008), pravastatin (Matsushima et al., 2005),
cyclosporin A (Masahiro et al., 2005), lopinavir (Agarwal et al., 2007), acetaminophen
(Xiong et al., 2000), temocaprilat (Ishizuka et al., 1997), enalapril (Liu et al., 2006), and
several antibiotics including cefbuperazone, cefoperazone, ceftriaxone, cefpiramide,
benzylpenicillin, and moxifloxacin (Ahmed et al., 2008; Chio et al., 2009; Kato et al.,
2008) are also substrates for the MRP2 transporter.

Because MRP2 has such diverse substrate specificity, it can alter the intracellular
concentration of many therapeutically used agents and toxicologically relevant
xenobiotics. For example, there was a 10-fold decrease in the rate of biliary excretion of
spiramycin, an antibiotic, in Mrp2 knockout mice (Xianbin et al., 2007). Other studies
showed a 1.7-1.9-fold increase in the plasma levels of the food-derived carcinogens IQ
(2-amino-3-methylimidazo[4,5-f]quinoline) and PhIP (2-amino-1-methyl 6phenylimidazo[4,5- b]pyridine), increases in serum levels of fexofenadine, and increases
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in the serum levels of methotrexate in Mrp2-/- mice versus wild-type mice (Matsushima et
al., 2008; Vlaming et al., 2006). Mrp2-deficient mice have decreased total bilirubin and
glutathione in bile, and increased levels of bilirubin in urine, indicating that urinary
excretion may serve as an alternate excretion pathway for certain compounds in these
mice (Vlaming et al., 2006). Mrp2-deficient rats had an 8.5-fold increase in the serum
concentration of ezetimibe, an anti-hyperlipidemic, which was associated with an
increase in urinary elimination and decrease in fecal elimination (Oswald et al., 2006).
Likewise, methotrexate serum concentrations were increased and biliary concentrations
were decreased in mice lacking Mrp2 (Vlaming et al., 2006).

Since many drugs are substrates for the same transporter, there is an increased risk
of serious adverse effects when these proteins are inhibited at the same time. It was
shown that the coadministration of the anti-inflammatory drugs indomethacin and
sulfasalazine, both substrates for MRP2, increased the absorption and decreased the
elimination of sulfasalazine in the small intestine (Dahan et al., 2010). Additionally, a
wide variety of nonsteroidal anti-inflammatory drugs, such as salicylate, ibuprofen,
tolmetin, naproxen, sulindac, etodolac, indomethacin, piroxicam, ketoprofen, diclofenac,
celecoxib, and phenylbutazone, all inhibit MRP2-mediated methotrexate transport in
vitro (El-Sheikh et al., 2007). The pretreatment of dexomethasone in rats reduced the
total clearance of methotrexate by 33%, suggesting that multiple substrates may decrease
the ability of MRP2 to eliminate drugs (Fuksa et al., 2010). This coadministration of
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MRP2 substrates or inhibitors could lead to the elongated or shorted effects of the drug,
and these types of drug-drug interactions need to be further investigated.

Assessing the transport of highly prescribed pharmaceuticals via MRP
transporters either alone or in mixtures is important to determine the potential for drugdrug interactions. In the present study, we examined fosinopril, an angiotensin
converting enzyme (ACE) inhibitor, and loratadine and desloratadine, both
antihistamines, to determine if they were substrates for the MRP transporters, and if so,
whether they could alter the transport and toxicity of one another.

2. Methods:
2.1 Cell Culture
Marin-Darby canine kidney (MDCK) cells and MDCK cells transfected with the
human MRP1 and MRP2 gene were a gift from Piet Borst (Netherlands Cancer Institute).
Cells were grown in DMEM containing 10% FBS, 1% L-glutamine, and 1%
penicillin/streptomycin at 37ºC in a 5% CO2 atmosphere. The cells were passaged
approximately every 4 days and were terminated at passage number 20.

2.2 Drug selection and cell viability assays
The drug index database (http://www.rxlist.com/top200.htm), which lists the 200
most-prescribed medications in the U.S, was scanned to determine potential MRP1 and
MRP2 substrates based upon molecular weight, excretion into the feces, and the
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formation of glucuronide conjugates. Based upon these criteria and preliminary
experiments, fosinopril, loratadine, and desloratadine were selected to determine if they
were substrates for the MRP transporters. Cell viability experiments were performed by
seeding 6x103 cells per well into 96 well plates. Cells were allowed to attach overnight
and the next day, the medium was replaced with 100µL medium containing the drug of
interest. The cells were incubated for 3 days with six increasing concentrations (n=5
wells per concentration) of vincristine (American Radiolabeled Chemicals, Saint Louis,
MO), loratadine (Sigma, St. Louis, MO), fosinopril (Sequoia Research Products Ltd,
Pangbourne, United Kingdom), desloratadine (Sigma), or methotrexate (American
Radiolabeled Chemicals). The MTS assay (Promega, Madison, WI) was used to assess
cell viability by spectrophotometry at 490nm. Each experiment was repeated two to three
times. LC50 values were determined using dose response curves produced in Graphpad.

2.3 Cellular Accumulation and Efflux
Cells were seeded into a 6 well plates at 1.8x105/well (4 wells/cell line) and were
allowed to become confluent over 3 days. After confluence, the medium was aspirated
off and pre-incubated with serum-free medium containing 100µM verapamil (Sigma) for
30 minutes. After pre-incubation, media was replaced with serum-free medium
containing 100µM verapamil and 34.2µM desloratadine (the LC25), 42µM loratadine (the
LC25), 100µM fosinopril (the LC95), 500nM [3H] vincristine (0.167µCi/well, American
Radiolabeled Chemicals), or 1µM [3H] methotrexate (0.167µCi/well, American
Radiolabeled Chemicals). Cells were allowed to accumulate the drug for time periods
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ranging for 0 to 6 hours. At the varying time point, cells were washed and scraped into 2
mL PBS. For [3H] vincristine and [3H] methorexate, the amount of compound remaining
in the cells was determined by scintillation counting.

For desloratadine and loratadine, 400µL of 1M NaOH was added (Amini et al.,
2004) and for fosinopril, 400µL of 1M HCl was added (Cui, 2007). All three drugs were
extracted into butanol/hexane (2:98), evaporated under nitrogen, and then the extract was
resuspended in methanol. The aqueous portion was used to determine protein
concentration of the cells. Efflux experiments were carried out similarly, except after
medium removal and washing, serum-free medium was placed back into each well, and
the cells were allowed to efflux their accumulated drugs for 0-30 minutes. The amount of
drug remaining in the cell was determined by a Waters HPLC equipped with a dual
absorbance wavelength detector and a Hypersil C18 Column (ES Industries, West Berlin,
NJ). For loratadine and desloratadine, detection was at 247nm, while detection for
fosinopril was at 220nm. The mobile phase for loratadine and desloratadine was
acetonitrile, 20mM dihydrogen phosphate, and triethylamine (43:57:0.02, v/v/v, pH 2.4)
with a flow rate of 1mL/mim (El-Sherbiny, 2007). The mobile phase for fosinopril was
acetonitrile, water, and ortho- phosphoric acid (4000:15:2, v/v/v) with a flow rate of
1mL/min (Kirschbaum, 1990).

2.4 Altered enzyme and gene expression in fosinopril dosed mice
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Male FVB mice (n=10) were obtained from Taconic and individually housed until
9 weeks of age. All experiments were approved by the IACUC at Clemson University.
Mice were gavaged for 3 days with water or 100mg/kg fosinopril (n=5 mice/group). The
animals were euthanized 6 hours after the final gavage, and blood, livers, small intestines,
gallbladders, and kidneys were collected. Serum was prepared from the blood and stored
at -20oC, while the organs were weighed and frozen at -80oC until analysis. Serum was
used to determine total bilirubin, ALT, and AST concentrations (Johnson & Johnson’s
VT250 Automatic Chemical Analyzer), while livers and kidneys were used to determine
transporter and phase II enzyme expression by QPCR.

2.5 QPCR
RNA was isolated from liver and kidneys of the mice using TriReagent (SigmaAldrich, St. Louis, MO). Two micrograms RNA was incubated with 0.2mM
deoxynucleotide mix, 2ng random hexamers, and 200U MMLV reverse transcriptase
(Promega, Madison, WI) for 1 hour at 37°C to prepare cDNA. The expression of Mrp1,
Mrp2, Mrp3, Mrp4, Bsep, UGT1A, and UGT2B was quantified by QPCR using SYBR
green (Bio-Rad, Hercules, CA) and the appropriate primers (Table 1). Standards were
prepared specifically for each gene to be analyzed using PCR and then purified using the
Qiagen PCR purification kit (Qiagen, Valencia, CA). The concentration of the purified
sample of cDNA was determined by spectrophotometry, and used to make serial
dilutions. Samples and standards were run in triplicate, and GAPDH was used as a
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housekeeper gene. Fold changes were determined by dividing gene levels of mice that
received fosinopril by wild-type mice gene levels.

2.6 Drug disposition in Mrp2-/- mice
Male FVB (control) and Mrp2 knockout mice (n=10 of each strain) were obtained
from Taconic and individually housed until 9 weeks of age. Five mice from each strain
received 50mg/kg [3H] methotrexate in saline via tail vein injection (Vlaming et al.,
2006), and five mice from each strain received 50mg/kg [3H] methotrexate via tail vein
injection plus 100mg/kg fosinopril via gavage. Mice were euthanized 1 hour later, since
the half-life of methotrexate in mice is ~30 minutes (Sani et al., 2010) and the half-life of
fosinopril in humans is ~12 hours (reviewed in Murdoch et al., 1992). Blood was
collected and spun to collect serum. Intact livers, kidneys, small intestines, colons, and
gallbladders with contents were collected and homogenized in PBS. An aliquot of the
homogenate or serum was used for scintillation counting to determine the amount of
methotrexate in each organ.

2.7 Data Analysis
Samples from each group were averaged and significant differences were
determined by ANOVA, followed by the appropriate post-hoc test, or by Student’s t-test
using Graphpad Prism Software (San Diego, CA).

3. Results:
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3.1 Drug sensitivity
The sensitivity of MDCK cells transfected with MRP1 and MRP2 to 3 high-use
pharmaceuticals, fosinopril, loratadine, and desloratadine was assessed, using the known
substrates vincristine and methotrexate as positive controls. MRP1-overexpressing cells
were 1.4-fold less sensitive to the toxicity of loratadine, while desloratadine showed no
differences in sensitivity (Table 2). In contrast, MRP1-overexpressing cells are 2.0-fold
and MRP2 are 2.4-fold less sensitive for fosinopril than controls (Table 2). These results
suggest that loratadine and fosinopril are potential substrates for MRP transporters.

3.2 Drug efflux assays
Preliminary experiments were conducted to determine the appropriate
accumulation time for each compound, which was 2 hours for fosinopril, 4 hours for
vincristine, 1 hour for loratadine, and 6 hours for desloratadine and methotrexate. After
cells were loaded with the drug, their rate of efflux was examined. Vincristine was
effluxed out of the MRP1-overexpressing cells more rapidly, with 56% of the compound
remaining in MRP1 cells after 20 minutes, compared to 85% remaining in the MDCK
cells (Figure 1A). The other positive control, methotrexate, showed 1.5-fold less
accumulation in MRP2 cells compared to controls (data not shown). For fosinopril, the
MRP2 cells only retained 13 % of their accumulated fosinopril while the MDCK cells
retained 60 % (Figure 1B). While MRP1 and MRP2 showed no real differences in their
ability to efflux loratadine (Figure 1C), MRP2-overexpressing cells effluxed
desloratadine significantly more rapidly, as 56% of the accumulated desloratadine
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remained in MRP2-overexpressing cells after 20 minutes compared to 66% retention in
the MDCK cells (Figure 1D).

Since fosinopril appeared to be a substrate for MRP2, we coincubated cells with
fosinopril and either loratadine, desloratadine, or methotrexate to determine if the second
drug would increase the retention of fosinopril. When fosinopril was combined with
desloratadine, its retention was increased by 2-fold (Figure 2A), with loratadine, its
retention was increased by 4.7-fold (Figure 2B), and with methotrexate, the retention was
increased by 2-fold (Figure 2C).

3.4 mRNA expression and serum chemistry in mice dosed with fosinopril
FVB mice were treated with fosinopril for 3 days to determine whether phase II
enzymes and transporters gene expression would be induced. There was a 2.1-fold
increase in liver Bsep mRNA expression (Table 3), but no other changes in enzyme gene
expression were seen. Additionally, there were no significant differences in serum AST,
ALT, or total bilirubin (data not shown).

3.5 Altered drug disposition in Mrp2-/- mice
Preliminary drug disposition experiments indicated that fosinopril serum
concentrations were below the HPLC detection limits. Therefore, [3H]methotrexate was
used to determine if fosinopril co-administration would alter methotrexate disposition.
When Mrp2 was lacking, fosinopril increased the accumulation of methotrexate in the
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liver by 2.1-fold and decreased methotrexate levels in the intestine by 1.5-fold (Figures
3A and B). While the gallbladder accumulated 2.9-fold less methotrexate when
combined with fosinopril, there were no differences between the wild-type and knockout
mice (Figure 3E). In both the serum and kidney, there was a significant 2.9-fold and 3fold increase, respectively, in methotrexate accumulation in the Mrp2 knockout mice.
The co-administration of fosinopril appeared to increase accumulation in the serum,
although this was not quite statistically significant (Figure 3D). However, fosinopril
coadministration did increase accumulation in the kidney (Figure 3C).

4. Discussion
The present study indicates that fosinopril is a substrate for the MRP2 transporter
based upon reduced toxicity to and an increased rate of elimination from MRP2overexpressing cells, as well as altered disposition in Mrp2-/- mice. Additionally,
fosinopril coincubation with other substrates for the MRP2 transporter increases
fosinopril retention and reduces its elimination, suggesting a potential for drug-drug
interactions.

Fosinopril is an ACE inhibitor, which is used in patients with cardiovascular
disease and hypertension. Approximately 3,155,000 prescriptions a year are written for
fosinopril, making it one of the most highly prescribed medications for hypertension
(http://www.rxlist.com/top200.htm). Our data indicates that fosinopril is a substrate for
MRP2, since it is both 2-fold less toxic to MRP2-overexpressing cells and is eliminated
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at a 4-fold faster rate in cells that overexpress MRP2 versus control cells. Like
fosinopril, other ACE inhibitors such as enalapril and temocapril were previously shown
to be substrates for the MRP2 transporter in vitro and in vivo (Ishizuka et al., 1997; Liu et
al., 2006). For example, in EHBR rats, which do not express functional Mrp2 protein,
the biliary excretion rate of enalapril is essentially 0 (Liu et al., 2006). Additionally,
studies have shown that temocapril was taken up into Mrp2-expressing membrane
vesicles to 3-fold higher levels than vesicles from EHBR rats, which lack Mrp2.
Similarly, in vivo studies show that temocapril serum levels were approximately 2- to 5fold higher in rats lacking Mrp2, which correlated with a 3-fold reduction in its biliary
elimination rate (Ishizuka et al., 1997; Takada et al., 2004). Likewise, the current study
indicates that fosinopril can increase methotrexate levels in the serum by 3- to 5-fold in
mice lacking Mrp2, which is similar in magnitude to the above studies using rats lacking
Mrp2. However, many other ACE inhibitors including benazepril, cilazapril, delapril,
trandolapril, and imidapril are not substrates for Mrp2 (Ishizuka et al., 1997; Shionoiri et
al., 2001).

Fosinopril, enalapril, and temocarpil are all known to be predominantly
eliminated in the bile, while most other ACE inhibitors are eliminated in the urine
(Murdoch and McTavish, 1992; Suzuki et al, 1993). Although the reasons for this high
propensity towards biliary excretion are unclear, it has been suggested that the carboxyl
groups within their chemical structures enable these three ACE inhibitors to be substrates
for the MRP2 transporter (Ondetti, 1988).
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Along with its transport by MRP2, studies have revealed that fosinopril can cause
cholestatic jaundice and liver failure in a short period of time after starting treatment
(Chou et al., 2008; Nunes et al., 2001). Similarly, enalapril has also been shown to
induce cholestasis in some patients (Hartleb et al., 2002; Muela et al., 2002; Todd et al.,
1990). These clinical findings add further credence to the ability of MRP2 to transport
fosinopril, symptoms of jaundice and cholestasis are also seen in rats and humans that
have mutations in MRP2 (Paulusma et al., 1996; Paulusma et al., 1997).

Next, we investigated changes in fosinopril elimination in the presence of a
second drug. There are 2-, 5-, and 2-fold increased levels of fosinopril that remain in cells
after coincubation with methotrexate, loratadine, and desloratadine, respectively. This
indicates that the two drugs may be competing for elimination. Other studies have shown
that dexomethasone can reduce the total clearance of methotrexate by 33% in rats,
showing that the use of multiple pharmaceuticals that are substrates for the same
transporter can decrease the clearance of the drugs (Fuksa et al., 2010). The
coadministration of indomethacin and sulfasalazine, both substrates for MRP2, decreased
the elimination of sulfasalazine in the small intestine by 7.5-fold (Dahan et al., 2010).
Additionally, a wide variety of nonsteroidal anti-inflammatory drugs, such as salicylate,
ibuprofen, tolmetin, naproxen, sulindac, etodolac, indomethacin, piroxicam, ketoprofen,
diclofenac, celecoxib, and phenylbutazone all inhibit MRP2-mediated methotrexate
transport in vitro (El-Sheikh et al., 2007). The drug-drug interaction that may result
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could alter toxicity of one or more of the compounds, and may also increase or decrease
the desired therapeutic effects.

Interestingly, the coincubation of loratadine and fosinopril resulted in a 5-fold
increase in fosinopril retention compared to the 2-fold increase with either methotrexate
or desloratadine. The reasons for this are unclear, but may be due to loratadine acting as
an inhibitor of MRP2 rather than a substrate, as the efflux rate of loratadine alone was not
very different between the three cell lines.

Next, [3H]methotrexate and fosinopril were coadministered to Mrp2-/- mice, since
methotrexate elimination is reduced in Mrp2 knockout mice (Vlaming et al., 2006). Our
study indicated that when methotrexate was given alone, its levels were increased by 3fold in the kidney and 2.9-fold in the serum of mice lacking Mrp2. This is consistent with
what others have seen, with a 2.2-fold increase in methotrexate levels in the serum
(Vlaming et al., 2006), and ~2-fold increase in levels of methotrexate in the kidney of
Mrp2 knockout mice (Vlaming et al., 2008). These other studies also reported a
significant shift from fecal to urinary elimination of methotrexate in mice lacking the
Mrp2 transporter (Vlaming et al., 2008). Similar findings have been reported for other
compounds in Mrp2-/- mice. For example, bilirubin levels are increased by 5-fold in the
serum and 6.7-fold in the urine of mice lacking Mrp2 (Chu et al., 2006).
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When fosinopril is given in combination with methotrexate in mice lacking Mrp2,
fosinopril increased the accumulation of methotrexate in the liver by 2.1-fold. This
change was expected because of the high expression of Mrp2 in the liver, and since Mrp2
is the predominant transporter that eliminates fosinopril and methotrexate (Keppler et al.,
1997; Vlaming et al., 2006). Additionally, the 1.5-fold decrease of methotrexate in the
intestines of mice lacking the Mrp2 protein, when given in combination with fosinopril,
suggests that Mrp2 is involved in the biliary secretion of both methotrexate and
fosinopril. Other studies have also reported a 2.3-fold decrease in intestinal levels of
methotrexate (Vlaming et al., 2006; Vlaming et al., 2009). This increase in methotrexate
concentrations in the liver, coupled with a decrease in intestinal concentrations, suggests
that fosinopril coadministration is causing a reduction in fecal elimination. In the
absence of Mrp2, there was a 3-fold and 2.9-fold increase in methotrexate levels in the
serum and kidney, respectively, when methotrexate was coadministered with fosinopril.
This again, suggests that when Mrp2 is lacking, fosinopril elimination shifts from the
feces to the urine. Although we did not see changes in mRNA expression in FVB mice
when treated with fosinopril, one possibility is that fosinopril is also a substrate for Mrp3,
which resulted in its movement from the liver into the serum. It is known that MRP2,
MRP3 and Bcrp can transport methotrexate and can all compensate for loss of one or
more of the transporters in the liver (Doyle et al., 2003; Masuda et al., 1997; Vlaming et
al., 2008; Vlaming et al., 2009; Volk et al., 2002; Zeng et al., 2001). Although MRP1,
MRP4, MRP5 and P-gp can transport methotrexate in vitro, these other transporters do
not appear to play a significant role in the elimination of methotrexate (Chen et al., 2002;
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De Graaf et al., 1996; Weilinga et al., 2005; Zeng et al., 2001). From the present study,
MRP1 does not appear to transport fosinopril and we attempted to minimize the effect of
P-glycoprotein by using verapamil. However, we cannot exclude the possibility that
Mrp3, Bcrp, Mrp4, and/or Bsep may also transport fosinopril.

In conclusion, MRP2 transports fosinopril and its efflux of fosinopril is reduced in
the presence of other compounds, such as methotrexate. These findings and the further
understanding of the ABC-transporters and their role in drug-drug interactions could
eventually help minimize side effects and aid in the better treatment of patients.
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Table 1 – QPCR primer sets
Primer

Forward 5’to 3’

Reverse 5’ to 3’

Tm (oC)

Mrp1

taatggaagcagacaaggcccaga

agaggccagtgcagatacatggtt

60

Mrp2

atggtcctagacagcggcaagatt

ttcacactttcaatgccggcttcc

60

Mrp3

agaaccaagcatcaaggtcccaga

aaggttctcaccaaagccctcaga

60

Mrp4

caaagctgcaagccacatcctcat

agaccaaattgaggcctcggagaa

60

UGT1A

gaaattgctgaggctttgggcaga

agagtgtgtgatgaatgcccgagt

60

UGT2B

agttgagacaatgggccaag

gttgggtgaggaaactccaa

61

Bsep

gctggtcatcactggagccccc

gcagccctcctgtgcttggc

60

GAPDH

gccttccgtgttcctacc

gcctgcttcaccaccttc

51
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Table 2. Drug sensitivity in cells overexpressing MRP1 and MRP2
LC50 Values
Drugs

MDCK

MRP1

MRP2

Loratadine (µM)

87.1±9.0

124.3±13.6*

96.9±4.4

Desloratadine (µM)

44.5±5.9

48.0±9.2

45.7±5.4

Fosinopril (µM)

188.2±68.1

372.4±47.0*

452.2±77.6*

Vincristine (nM)

456.2±137.0

1373.9±143.0 *

494.9±113.6 *

Methotrexate (nM)

38.5±13.3

63.0± 26.1*

53.0± 9.5*

LC50 values + SD are averaged from three to four separate experiments. Statistical
differences between control and transfected cell lines (*) were determined by ANOVA
followed by Tukey’s (p<0.05).
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Table 3. mRNA levels in liver and kidneys of mice treated with 100mg/kg fosinopril
Name

Liver (molecules)

Kidney (molecules)

Control

Fosinopril

Fold
Change

Control

Fosinopril

Fold
Change

Mrp1

9.4±2.3

12.3±5.6

1.3

109.6±39.9

194.5±197.7

1.8

Mrp2

1,378±325

1,286±366

0.9

1,317±229

2,462±2,002

1.9

Mrp3

774.8±301.6

815.8±550.1

1.1

28.6±6.0

55.6±59.7

1.9

Mrp4

275.6±146.4

335.9±283.8

1.2

11,589±1,359

15,945±13,280

1.4

Ugt1A

1,798±729

2,139±1,283

1.2

2,940±825

5,240±5,492

1.8

Ugt2B

65,511±32,965

83,463±58,067

1.3

80,868±24,831

92,016±55,931

1.1

Bsep

9,830±2641

20,490±11,651

2.1*

247.6±43.5

438.1±304.2

1.8

The number of molecules + SD are the average of 4-5 mice, each run in triplicate.
Statistical differences (*) were determined by Student’s t-test (p<0.05).
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Figure 1. Efflux of drugs from MDCK, MRP1 and MRP2 cells.
MDCK (•), MRP1 (∆) and MRP2 (O) cells were allowed to accumulate vincristine (A),
fosinopril (B), loratadine (C), and desloratadine (D), and then efflux was measured by
HPLC or scintillation counting as percent remaining in the cell. Data is presented as the
average percentage efflux + standard deviation (n=4-12) of the average of two to three
combined trials. Statistical analysis was performed by ANOVA followed by Tukey’s
(p<0.05; A=MRP1 vs. MDCK; B=MRP2 vs. MDCK).

Figure 2. Fosinopril concentrations remaining in the MRP2 cells are increased
when a second substrate is present.
Fosinopril was allowed to accumulate for 2 hours, and then efflux for twenty minutes.
Fosinopril remaining in the cell was then measured by HPLC. Controls were dosed with
100uM fosinopril and mixtures with either 10, 15, 25uM desloratadine (A), loratadine
(B), or 30, 50nM methotrexate (C), along with 100uM fosinopril, and then analyzed.
Data is presented as the average percentage efflux + standard deviation (n=4-8) of the
average of two combined trials. Statistical differences between fosinopril alone and
fosinopril plus the second drug (*) were determined by ANOVA followed by Tukey’s
(p<0.05).
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Figure 3. Fosinopril alters [3H] methotrexate disposition in FVB and FVB/Mrp2-/mice.
FVB and Mrp2-/- mice (KO) were injected with 50mg/kg [3H]methotrexate (MTX) with
or without 100mg/kg fosinopril (Fos). The amount of [3H] methotrexate remaining in the
organs and serum was measured by scintillation counting; A (liver), B (small intestine), C
(kidney), D (serum), E (gallbladder), F (colon). Data is presented as the average
percentage remaining + standard deviation (n=4-5 mice per group). Statistical
differences (*) were determined by Student’s t-test (p<0.05).
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5. Conclusion
In the past few decades, the prescription of multiple pharmaceuticals has become
commonplace in the United States. Every year there is more and more potential for
injuries to occur, due to the lack of knowledge of certain drug-drug interactions. Some of
the prominent mechanisms for toxicity and drug-drug interactions for many highly used
pharmaceuticals are through the MRP transporters. Expanding our knowledge of these
transporters and the interactions that may occur when confronted with multiple
compounds is essential to avoid complications. We wanted to determine if certain highly
used pharmaceuticals are substrates for MRP1 and/or MRP2, and if so, whether the coadministration of these compounds results in reduced elimination and altered toxicity. In
conclusion, we have shown in vitro that the MRP2 transporter is one of the major
transporters of some highly prescribed pharmaceuticals. We have demonstrated that
when fosinopril is in the presence of other compounds, either substrates or potential
inhibitors, concentrations can be increased significantly. This could lead to serious
physiological damages and even fatalities. Our in vivo experiments further supported that
MRP2 is a key eliminator of methotrexate and fosinopril. In these experiments we
demonstrated that the co-administration of methotrexate and fosinopril can lead to
increased concentration of drugs, and that the absence of the Mrp2 transporter leads to
even higher concentration in the liver, kidney, and serum. This is one example of the
type of drug-drug interactions that can occur when a combination of several
pharmaceuticals are used.
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It can be assumed that repeated use of more than one substrate for the MRP2
transporter could result in toxic levels of one or all drugs involved. The respective half
lives of fosinopril, loratadine, desloratadine and methotrexate are 12, 12, 27 hours and 30
minutes (reviewed in Murdoch et al., 1992; Sani et al., 2010; www.merk.com). Usually,
doses taken for adults are 10mg for fosinopril and loratadine once daily, 5mg every other
day for desloratadine, and 15 to 30mg of methotrexate for a course of 5 days
(www.merk.com; www.rxlist.com). Lethalilty in mice was found to occur at 2,600mg/kg
fosinopril, 5000mg/kg loratadine, 250mg/kg desloratadine and at total dose of 1.5 grams
of methotrexate (www.rxlist.com). With regular use, the chances of fosinopril, loratadine
and desloratadine reaching toxic levels is unlikely, due the very high doses that would
need to be reached to produce toxic effects. Due to the high dose treatment of
methotrexate, the chances of toxic levels of methotrexate being reached in combination
with one or more of the described drugs is very likely. The combination with fosinopil
especially, has shown to increase the concentration of methotrexate remaining in the
intestine, serum and kidneys of our wild-type mice. Special care should be taken to avoid
the use of methotrexate and fosinopril, because of the potential for toxic levels to be
reached.

To better explain how the body reacts to and regulates the potential high
concentration of drugs in the presence of each other, studies to see if certain drugs can
activate the ligand binding domain of the nuclear receptors, constitutive androstane
receptor and pregnane X receptor could be conducted. These nuclear receptors mediate
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the transcription of genes such as CYP3A4, glucuronosyltransferases, multidrug
resistance-associated protein 2 and bile salt efflux protein (Kast et al., 2002; Johnson et
al., 2002; Mackenzie et al., 2003), which are responsible for the metabolism of many
endogenous compounds, therapeutic drugs, and xenobiotics such as bile salts,
dexamethasone and phenobarbital (Byrne et al., 2002; Kast et al., 2002; Johnson et al.,
2002). Activation of nuclear receptors increases the clearance of compounds from the
body by increasing the levels of proteins responsible for elimination. Although our
mRNA data does not support that fosinopril is a ligand for the nuclear receptors, we did
not examine protein levels of glucuronosyltransferases or ABC transporters, which may
indeed be upregulated. One way to quickly examine whether fosinopril activates PXR
and CAR would be to examine Cyp2b expression, which is the best biomarker for
activation by these nuclear receptors.

Mice lacking multiple genes is becoming a very useful tool in evaluating the
metabolism of compounds. The use of a multiple gene knockout mice could aid in the
explaining some of the potential compensatory mechanisms that may be occurring to
reduce concentrations of drugs when one or more transporters are eliminated or impaired.
For example, when only the Mrp2 protein is absent in mice, total bilirubin in plasma is
increased by 5-fold (Chu et al., 2006; Vlaming et al., 2006), while mice lacking both the
Mrp2 and Bcrp transporters have a 7.5-fold increase in plasma levels of bilirubin
(Vlaming et al., 2009). These changes in substrate concentrations when more than one
ABC transporters is absent can also be shown with the drug methotrexate. In the absence
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of Mrp2 alone, plasma concentrations of methotrexate are increased 2.5-fold (Vlaming et
al., 2006). When mice lacking the Bcrp transporter are dosed with methotrexate, there is
a 1.6-fold increase in the concentration of methotrexate in the plasma, while mice lacking
both the Mrp2 and Bcrp transporters have a 3.3-fold increase in plasma methotrexate
concentrations (Vlaming et al., 2009). These studies indicate that in the absence of more
than one transporter, the concentrations of compounds increase significantly. In our
study, we only examined a single gene, Mrp2, and its effect on fosinopril disposition.
The next step in our research should be to examine whether multiple transporters can
eliminate fosinopril. Some potential transporters to examine would include Bsep, since
its expression was upregulated in the livers of mice dosed with fosinopril. Another
transporter to examine is Bcrp, since the double knockout of both Mrp2 and Bcrp
significantly changes the disposition of methotrexate. Knowing whether these 2 proteins
were upregulated and/or could transport fosinopril may help in explaining the some of
our disposition results, such as why we see increased levels of methotrexate in the
intestine of mice that received both methotrexate and fosinopril. The more we can
uncover about these transporters and how they work in combination with each other will
help in reducing complications and aid in the more effecting administration of therapeutic
drugs.

As can be seen, the metabolism of many pharmaceuticals is a very complex
system and the further study of these potentially dangerous drug-drug interactions that
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occur between highly prescribed pharmaceuticals and the physiologic changes that result
is an important area of study to minimize harm to patients.
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